NCT04413942 - Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

June 30, 2022

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL

FB825

Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE

OTHER

Placebo

Formulation buffer

Trial Locations (18)

19103

Paddington Testing Co, Inc, Philadelphia

23226

Clinical Research Partners, Richmond

32720

University Clinical Research - Deland, LLC, DeLand

33016

Sweet Hope Research Specialty, Hialeah

33027

FXM Clinical Research Miramar, LLC, Miramar

33030

Universal Axon - Homestead, LLC, Homestead

33175

FXM Clinical Research Miami, LLC, Miramar

33308

FXM Clinical Research Ft. Lauderdale, LLC., Fort Lauderdale

33609

Moore Clinical Research, Tampa

33613

Avita Clinical Research (PCRS Network), Tampa

48084

Revival Research Institute, LLC, Troy

48326

Oakland Hills Dermatology (PCRS Network), Auburn Hills

90212

Zenith Research, Beverly Hills

91436

Encino Research Center, Encino

91606

Providence Clinical Research, North Hollywood

92119

ACRC Studies, San Diego

92647

Marvel Research 002, LLC, Huntington Beach

991403

Unison Clinical Trials, Sherman Oaks